Zacks Investment Research upgraded shares of Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) from a hold rating to a buy rating in a research note published on Wednesday. They currently have $0.75 price objective on the biotechnology company’s stock.

According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “

Separately, HC Wainwright set a $10.00 price target on Ohr Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 16th.

Shares of Ohr Pharmaceuticals (NASDAQ OHRP) opened at 0.6489 on Wednesday. The firm’s market cap is $36.48 million. The company has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.67. Ohr Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $3.20.

Ohr Pharmaceuticals (NASDAQ:OHRP) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.18. Analysts forecast that Ohr Pharmaceuticals will post ($0.95) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ohr Pharmaceuticals, Inc. (OHRP) Upgraded by Zacks Investment Research to “Buy”” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at

Large investors have recently bought and sold shares of the stock. Cannell Peter B & Co. Inc. bought a new stake in Ohr Pharmaceuticals during the second quarter valued at $187,000. Renaissance Technologies LLC lifted its stake in Ohr Pharmaceuticals by 242.3% during the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 162,600 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Ohr Pharmaceuticals by 0.7% during the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 5,481 shares during the last quarter. 7.03% of the stock is owned by institutional investors.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Get a free copy of the Zacks research report on Ohr Pharmaceuticals (OHRP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.